Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,
Opp. PCI, Ankleshwar – 393 002,
Gujarat, India
Tel : (02646) 220774
Fax : (02646) 251291
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square,
M. A. Road, Andheri (West),
Mumbai – 400 058, India.
Tel : (91-22) 26701050/1/2
Fax : (91-22) 26701053
Email: samrat@bom4.vsnl.net.in

13 December, 2017

To,
Department of Corporate Services,
Bombay Stock Exchange Limited
25th Floor, P J Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sir,

Sub: Un-Audited Financial Results f.t.q.e. 30/09/2017

We write this to inform you that at a Board Meeting held today i.e. Wednesday, the 13th day of December, 2017, the Board has considered and adopted the attached Un-Audited Financial Results of the company for the quarter ended 30th September, 2017. The Limited Review Report of the Statutory Auditor is also attached.

Kindly inform all your members.

Thanking you,

Yours faithfully,
For Samrat Pharmachem Limited

Lalit Mehta
Managing Director

Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

Statement of Standalone Unaudited Results for the Quarter Ended 30 September, 2017

(Rupees in Lakhs)

Particulars	Quarter Ended 30-Sep-17 (Unaudited)	Quarter Ended 30-Jun-17 (Unaudited)	Quarter Ended 30-Sep-16 (Unaudited)	Year to date ended 30-Sep-17 (Unaudited)	Year to date ended 30-Sep-16 (Unaudited)
1 (a). Revenue from Operations	**2,077.40**	2,021.90	1,864.97	**4,099.30**	3,992.36
(b). Other Income	**2.37**	1.63	1.94	**4.00**	11.54
Total Revenue	**2,079.77**	2,023.53	1,866.91	**4,103.30**	4,003.90
2. Expenditure					
a) Cost of materials consumed	**1,750.18**	1,834.80	1,731.83	**3,584.97**	3,654.84
b) Purchase of Traded Goods	**65.98**	0.00	0.00	**65.98**	0.00
c) Change in Inventories of Finished Goods and Work-in-Progress	**49.12**	(62.15)	(79.64)	**(13.03)**	(46.38)
d) Employee Costs	**33.11**	26.92	23.63	**60.03**	45.74
e) Interest	**19.36**	19.48	15.49	**38.84**	32.88
f) Depreciation & Amortisation expense	**11.08**	10.32	11.60	**21.40**	22.73
g) Other Expenses	**86.28**	93.17	100.39	**179.46**	191.29
Total	**2,015.11**	1,922.54	1,803.30	**3,937.65**	3,901.10
3. Profit before exceptional & extraordinary items & tax	**64.66**	100.99	63.61	165.65	102.80
4. Exceptional Items	**0.00**	0.00	0.00	0.00	0.00
5. Profit before extraordinary items & tax	**64.66**	100.99	63.61	165.65	102.80
6. Extraordinary items	**0.00**	0.00	0.00	**0.00**	0.00
7. Profit before tax	**64.66**	100.99	63.61	**165.65**	102.80
8. Tax expense					
a) Current Tax	**(15.91)**	(30.29)	(12.90)	**(46.20)**	(24.66)
b) Deferred Tax	**2.26**	(11.03)	(0.43)	**(8.77)**	(2.97)
Total Tax Expense	**(13.65)**	(41.32)	(13.33)	**(54.97)**	(27.63)
9. Profit (Loss) for the period after tax	**51.01**	59.67	50.28	**110.68**	75.17
10. Other Comprehensive Income (OCI)					
a(i) Items that will not be re-classified to profit and loss	**0.00**	0.00	0.00	**0.00**	0.00
(ii) Income tax relating to items that will not be re-classified to profit and loss	**0.00**	0.00	0.00	**0.00**	0.00
b(i) Items that will be re-classified to profit and loss	**0.00**	0.00	0.00	**0.00**	0.00
(ii) Income tax relating to items that will be re-classified to profit and loss	**0.00**	0.00	0.00	**0.00**	0.00
Total Other comprehensive income, net of income tax	**0.00**	0.00	0.00	**0.00**	0.00
11. Total Comprehensive Income for the period	**51.01**	59.67	50.28	**110.68**	75.17
12. Paid-up Equity Share Capital (Face Value Rs.10)	**308.97**	308.97	308.97	**308.97**	308.97
13. Earnings per equity share					
a) Basic	**1.65**	1.93	1.63	**3.58**	2.43
b) Diluted	**1.65**	1.93	1.63	**3.58**	2.43

Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

Statement of Assets & Liabilities

(Rs. in lakhs)

PARTICULARS	Standalone AS ON 30-Sep-17 Un-Audited
ASSETS	
NON - CURRENT ASSETS	
(a) Fixed Assets	
(i) Tangible	703.67
(ii) Intangible	3.61
(iii) Capital Work-in-progress	-
(b) Non-Current Investment	0.10
(c) Deferred Tax Assets (Net)	-
(d) Long-Term Loans And Advances	20.91
(e) Other Non-Current Assets	119.48
Sub total- Non Current Assets	**847.77**
CURRENT ASSETS	
(a) Current Investment	-
(b) Inventories	1,011.45
(c) Trade Receivables	1,718.80
(d) Cash And Cash Equivalents	412.55
(e) Short Term Loans And Advances	-
(f) Other Current Assets	190.00
Sub total- Current Assets	**3,332.80**
Total- Assets	**4,180.57**
EQUITY AND LIABILITIES	
SHAREHOLDERS' FUNDS:	
(a) Share Capital	308.97
(b) Reserves And Surplus	1,338.12
Sub total- Shareholders' Fund	**1,647.09**
NON - CURRENT LIABILITIES	
(a) Long-Term Borrowings	97.45
(b) Deferred Tax Liabilities (Net)	39.13
(c) Other Long-Term Liabilities	-
(d) Long-Term Provisions	-
Sub total- Non Current Liabilities	**136.58**
CURRENT LIABILITIES	
(a) Short-Term Borrowings	600.18
(b) Trade Payables	1,747.35
(c) Other Current Liabilities	3.17
(d) Short-Term Provisions	46.20
Sub total- Current Liabilities	**2,396.90**
Total- Equity and Liabilities	**4,180.57**

Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

Notes:

1. The above results were reviewed by the Audit Committee of the Board of Directors.
2. The Statutory Auditors have carried out a limited review of the results for the quarted ended 30 September, 2017.
3. The above unaudited results have been taken on record by the Board of Directors at it Meeting held on Wednesday, 13 December 2017 at the Corporate Office of the Company.
4. The Company has adopted Indian Accounting Standards ('Ind AS') notified by the Ministry of Corporate Affairs with efffect from 01 April 2017 (with a transition date of 01 April 2016). Accordingly the financial results for the quarter ended 30 September 2017 have been prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015 as prescribed under section 133 of the Companies Act, 2013.
5. The Ind AS compliant financial results pertaining to the quarter ended 30 September 2016 have not been subjected to any limited review or audit. However, the management has exercised necessary due diligence to ensure such financial results provide a true and fair view of the results.
6. Reconciliation between standalone financial results reported under erstwhile Indian GAAP and Ind AS:

Description	Quarter ended 30-Sep-16	Half year ended 30-Sep-16
Net Profit after tax as per Indian GAAP	41.74	66.63
Ind AS Adjustments		
- Restatement of expense	8.54	8.54
Other Comprehensive Income	0.00	0.00
Total Comprehensive Income as per Ind AS	50.28	75.17

7. There is a possibility that this quarterly and half yearly financial results may require adjustment before constituting the final IND-AS financial statements as at end for the year ending March 31, 2018, due to changes in financial reporting requirements arising from new or revised standards or interpretation issued by MCA / Appropriate Authority or changes in the use of one or more optional exemptions from full retrospective application of certain IND-AS as permitted under IND-AS-101.
8. The Company manufactures phamaceutical chemicals, which is a single business segment.
9. Figures for the previous period have been regrouped / reclassfied, wherever necessary.

By order of the Board of Directors
For Samrat Pharmachem Limited

Rajesh Mehta
Executive Director
DIN: 00216731

Place : Mumbai
Date : 13 December 2017

Shah & Savla LLP
Chartered Accountants

CA Mulesh Savla — Advisory & Regulatory
CA Ashit Shah — Indirect Tax
CA Deepali Mehta — Indirect Tax
CA Nilesh Dedhia — Direct Tax & Litigation
CA Miral Nagda — Audit & Assurance

LIMITED REVIEW REPORT

To Board of Directors
Samrat Pharmachem Limited

1. We have reviewed the accompanying statement of unaudited financials result of Samrat Pharmachem Limited, for the Quarter ended 30th September, 2017 and year to date from 1st April, 2017 to 30th September, 2017 attached herewith being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as modified by SEBI circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement is responsibility of the Company's Management and has been approved by the Board of Directors / Committee of Board of Directors. Our responsibility is to issue a report on these financials statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim financial information performed by Independent Auditor of the entity". A review of interim financial information consist of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.

3. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) under section 133 of the companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules,2014 and other recognized accounting policies and practices has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as modified by SEBI circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016 and rules made there under, including the manner in which it is to be disclosed, or that it contains any material misstatement.

4. We were neither engaged to review nor have we reviewed the comparative figures for the Quarter ended September 30th, 2016 and accordingly we do not express any review report on the results in the statement for the quarter ended September 30th, 2016 and year to date from 1st April, 2016 to 30th September, 2016 as set out in the note to the statement, these financial information have been complied by the management.

For SHAH & SAVLA LLP
Chartered Accountants
Firm Reg: No.:109364W

SHAH & SAVLA LLP ★ FRN-109364 W MUMBAI ★ Chartered Accountants

CA. Miral H. Nagda
(Partner)
Membership No. 108135
Place: Mumbai
Date: 13 DEC 2017